Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer

International Journal of Radiation Oncology Biology Physics

Volumn 80, Issue 2, 2011, Pages 476-482

  Small Jr , William ^a   Mulcahy, Mary F ^a   Rademaker, Alfred ^a   Bentrem, David J ^a   Benson, Al B ^a   Weitner, Bing Bing ^a   Talamonti, Mark S ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

3D conformal radiotherapy; Bevacizumab; Gemcitabine; Pancreatic cancer; Survival

Indexed keywords

3D-CONFORMAL RADIOTHERAPY; BEVACIZUMAB; GEMCITABINE; PANCREATIC CANCERS; SURVIVAL;

CARBOHYDRATES; DISEASES; HIGH ENERGY PHYSICS; RADIOTHERAPY; SURGERY; TOXICITY; TUMORS;

THREE DIMENSIONAL;

BEVACIZUMAB; CA 19-9 ANTIGEN; GEMCITABINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIAGNOSTIC IMAGING; DIARRHEA; DRUG DOSE REGIMEN; FATIGUE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS SURGERY; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; SIDE EFFECT; THREE DIMENSIONAL CONFORMAL RADIOTHERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEUTROPENIA; PANCREATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION;

EID: 79955620158     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2010.02.030     Document Type: Article

References (38)

1. H. Oettle, S. Post, and P. Neuhaus Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial JAMA 297 2007 267 277 (Pubitemid 46143304)
2. J.K. Park, Y.B. Yoon, and Y.T. Kim Survival and prognostic factors of unresectable pancreatic cancer J Clin Gastroenterol 42 2008 86 91
3. R.V. Tse, L.A. Dawson, and A. Wei Neoadjuvant treatment for pancreatic cancer: A review Crit Rev Oncol Hematol 65 2008 263 274
4. T.S. Lawrence, E.Y. Chang, and T.M. Hahn Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine Int J Radiat Oncol Biol Phys 34 1996 867 872
5. A.W. Blackstock, S.A. Bernard, and F. Richards Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer J Clin Oncol 17 1997 2208 2212
6. M.S. Talamonti, P.J. Catalano, and D.J. Vaughn Eastern Cooperative Oncology Group phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity J Clin Oncol 18 2000 3384 3389
7. R.A. Wolff, D.B. Evans, and D.M. Gravel Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma Clin Cancer Res 7 2001 2246 2253 (Pubitemid 32751621)
8. W. Small Jr., J. Berlin, and G.M. Freedman Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: A multicenter phase II trial J Clin Oncol 26 2008 942 947 (Pubitemid 351398088)
9. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342 (Pubitemid 38702844)
10. B.J. Giantonio, P.J. Catalano, and N.J. Meropol Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544 (Pubitemid 46733080)
11. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
12. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
13. W. Vervenne, J. Bennouna, and Y. Humblet A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer [abstract 4507] J Clin Oncol 26 Suppl 15 2008 214S
14. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Pancreatic adenocarcinoma, V.I. 2009. http://www.nccn.org/ professionals/physician-gls/PDF/pancreatic.pdf.
15. National Cancer Institute. Common terminology criteria for adverse events, v3.0 (CTCAE). August 9, 2006. http://ctep.info.nih.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf.
16. P. Therasse, S. Arbuck, and E. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. H.L. Kindler, G. Friberg, and D.A. Singh Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 23 2005 8033 8040 (Pubitemid 46657405)
18. C.G. Willett, D. Chung, and D. Sahani Phase I study of neoadjuvant bevacizumab, 5-fluorouracil, and radiation therapy followed by surgery for patients with primary rectal cancer [abstract 3589] J Clin Oncol 22 Suppl 14 2004 267S
19. C.H. Crane, L.M. Ellis, and J.L. Abbruzzese Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer J Clin Oncol 24 2006 1145-1151
20. E. Kaplan, and P. Meier Nonparametric estimation of incomplete observations J Am Stat Assoc 53 1958 457 481
21. M.H.G. Katz, P.W.T. Pisters, and D.B. Evans Borderline resectable pancreatic cancer: The importance of this emerging stage of disease J Am Coll Surg 206 2008 833 846
22. G.R. Varadhachary, E.P. Tamm, and J.L. Abbruzzese Borderline resectable pancreatic cancer: Definitions, management, and the role of preoperative therapy Ann Surg Oncol 13 2006 1035 1046 (Pubitemid 44337962)
23. J.D. Wayne, E.K. Abdalla, and R.A. Wolff Localized adenocarcinoma of the pancreas: The rationale for preoperative chemoradiation Oncologist 7 2002 34 45 (Pubitemid 34151106)
24. N. Ferrara, and R.S. Kerbel Angiogenesis as a therapeutic target Nature 438 2005 967 974 (Pubitemid 43093963)
25. J. Itakura, T. Ishiwata, and H. Friess Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression Clin Cancer Res 3 1997 1309 1316 (Pubitemid 27362391)
26. M. Niedergethmann, R. Hildebrand, and B. Wostbrock High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas Pancreas 25 2002 122 129 (Pubitemid 34815907)
27. Y. Seo, H. Baba, and T. Fukuda High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma Cancer 88 2000 2239 2245 (Pubitemid 30247122)
28. M. Bockhorn, Y. Tsuzuki, and L. Xu Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts Clin Cancer Res 9 2003 4221 4226 3 (Pubitemid 37204043)
29. J. Wang, Y.Q. Shi, and J. Yi Suppression of growth of pancreatic cancer cell and expression of vascular endothelial growth factor by gene silencing with RNA interference J Dig Dis 9 2008 228 237
30. H.L. Kindler, D. Niedzwiecki, and D. Hollis A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) [abstract 4508] J Clin Oncol 25 Suppl 18S 2007 199S
31. H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 2005 671 680 (Pubitemid 40216420)
32. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147 (Pubitemid 38524883)
33. V.K. Gupta, N.T. Jaskowiak, and M.A. Beckett Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance Cancer J 8 2002 47 54
34. B.G. Czito, J.C. Bendell, and C.G. Willett Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: phase I trial results Int J Radiat Oncol Biol Phys 68 2007 472 478 (Pubitemid 46694189)
35. C.H. Crane, K. Winter, and W. Regine A phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: RTOG PA0411 [abstract A-136] Int J Radiat Oncol Biol Phys 69 Suppl 2007 S77 S78
36. A. Lai, E. Filka, and B. McGibbon Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability Int J Radiat Oncol Biol Phys 71 2008 1372 1380
37. P.H. Gutin, F.M. Iwamoto, and K. Beal Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 75 2009 156 163
38. G.R. Varadhachary, R.A. Wolff, and C.H. Crane Preoperative gemcitabine (gem) and bevacizumab (bev)-based chemoradiation for resectable pancreatic adenocarcinoma [abstract 4630] J Clin Oncol 24 Suppl 15 2008 245S